TAF is the latest oral antiviral drug available in China, which is not yet a complete cure for hepatitis B. Patients with hepatitis B can control their disease with regular antiviral treatment, as can TAF, which is mainly a nucleoside antiviral drug with strong antiviral efficacy and a long treatment course. For most patients, the course of antiviral therapy is at least 4 years, and in the case of patients with cirrhosis, it needs to be taken for life. When using TAF, it is important to regularly monitor changes in liver function, hepatitis B DNA and the five indicators of hepatitis B.